Belite Bio, Inc·Healthcare
Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) CFO Hao-Yuan Chuang sold 6,200 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $181.50, for a total transaction of $1,125,300.00. Following the transaction, the chief financial officer owned 93,800 shares
Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) CEO Yu-Hsin Lin sold 9,200 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $181.45, for a total value of $1,669,340.00. Following the completion of the sale, the chief executive officer directly
Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website (https:// www.belitebio.com ). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).
Belite Bio (NASDAQ: BLTE - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Analyst Ratings This is a summary of current
Belite Bio (NASDAQ: BLTE - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earning report page for the
